Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Conditions

• Advanced/Metastatic Non-Small Cell Lung Cancer
• Carcinoma, Non-Small Cell Lung
• Non-Small Cell Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• PF-08634404 — BIOLOGICAL
  -Concentrate for solution for infusion
• Sigvotatug Vedotin — BIOLOGICAL
  -Powder for concentrate for solution for infusion. Single use vial
• Combination Agent 1 — BIOLOGICAL
  -Powder for concentrate for solution for infusion. Single use vial.

Study Details

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments. To join in the study, participants must: * Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread The study will look at: * Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease. * Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors. The study has different parts, each testing PF-08634404 with a different cancer medicine: * Part A will test PF-08634404 with a medicine called sigvotatug vedotin. * Part B of the study will look at how well the new medicine PF-08634404 works when used together with another medicine. Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Key Dates

Start date

Jan 30, 2026

Status verified

Jun 2026

Primary completion

Mar 8, 2029

Completion

Aug 23, 2033

Study Design

Enrollment

162 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: PF-08634404 + Sigvotatug Vedotin (Part A)
  Participants will receive PF-08634404 in combination with Sigvotatug Vedotin.
• Experimental: PF-08634404 + Combination Agent 1 (Part B)
  Participants will receive PF-08634404 in combination with other anticancer agents as per protocol.

Primary Outcome Measure

Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Through 90 days after the last study intervention; Up to approximately 5 years ]

Central Contacts

• Pfizer CT.gov Call Center
  1-800-718-1021
  [email protected]

Locations (27)

Find similar trials in Fayetteville, AR

Related Studies

• Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
  PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
• JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
  PHASE3 · Recruiting · University of Texas Southwestern Medical Center · La Jolla, California
• Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
  Recruiting · University of Colorado, Denver · Aurora, Colorado
• VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
  PHASE1/PHASE2 · Recruiting · VM Oncology, LLC · Santa Rosa, California